Business
InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa
Marks the first time a Phase 2 trial has studied a cannabinol (CBN) formulation as a treatment option for any disease Data expected to be released in early
About this update from Inmed Pharmaceuticals Inc.
[{"type":"text","content":"\nMarks the first time a Phase 2 trial has studied a cannabinol (CBN) formulation as a treatment option for any disease\nData expected to be released in early calendar Q3 2023\n\nVancouver, British Columbia--(Newsfile Corp. - March 28, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (\"InMed\" or the \"Company\"), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announced it has concluded enrollment of its Phase 2 clinical trial using investigational drug INM-755 cannabinol (\"CBN\") cream for the treatment of patients with epidermolysis bullosa (\"EB\"), a rare genetic skin disease.\nThe Phase 2 study, called INM-755-201-EB, enrolled 19 patients. All four subtypes of inherited EB, including EB Simplex, Dystrophic EB, Junctional EB, and Kindler Syndrome were accepted into the trial. The clinical trial is evaluating the safety of INM-755 cannabinol cream and its preliminary efficacy in treating symptoms of itch, pain, and wound healing in patients with epidermolysis bullosa. The study used a within-patient, double-blind design whereby matched index areas are randomized to INM-755 (cannabinol) cream or vehicle cream as a control. Results from this Phase 2 study of INM-755 CBN cream are expected to be released early calendar Q3 2023.\n\"We are delighted to have enrolled 19 patients in InMed's Phase 2 clinical trial of INM-755 cannabinol cream for EB, a rare disease that has major unmet medical needs,\" stated Alexandra Mancini, Senior Vice President of Clinical and Regulatory Affairs at InMed. \"We are hopeful results from this Phase 2 study will provide an indication that INM-755 CBN cream may provide symptomatic relief for EB patients. I would personally like to thank all the medical staff at the various sites and our clinical research organization who worked diligently to maximize enrollment, especially considering the challenges of enrolling patients with this extremely rare disease.\"\n\"Enrollment completion of this Phase 2 clinical trial of a cannabinol formulation represents an important milestone for InMed and the scientific community studying rare cannabinoids,\" said Eric A. Adams, InMed's President and CEO. \"As a class of compounds, we believe cannabinoids hold tremendous therapeutic potential for their innate interaction with the body, however,...